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LipidomicsCancer is a complex disease involving numerous biological processes, which can exist in parallel, can be
complementary, or are engaged when needed and as such can replace each other. This redundancy in
possibilities cancer cells have, are fundamental to failure of therapy. However, intrinsic features of tumor
cells and tumors as a whole provide also opportunities for therapy. Here we discuss the unique and speci-
fic makeup and arrangement of cell membranes of tumor cells and how these may help treatment.
Interestingly, knowledge on cell membranes and associated structures is present already for decades,
while application of membrane modification and manipulation as part of cancer therapy is lagging.
Recent developments of scientific tools concerning lipids and lipid metabolism, opened new and previ-
ously unknown aspects of tumor cells and indicate possible differences in lipid composition and mem-
brane function of tumor cells compared to healthy cells. This field, coined Lipidomics, demonstrates
the importance of lipid components in cell membrane in several illnesses. Important alterations in cancer,
and specially in resistant cancer cells compared to normal cells, opened the door to new therapeutic
strategies. Moreover, the ability to modulate membrane components and/or properties has become a
reality. Here, developments in cancer-related Lipidomics and strategies to interfere specifically with can-
cer cell membranes and how these affect cancer treatment are discussed. We hypothesize that combina-
tion of lipid or membrane targeted strategies with available care to improve chemotherapy, radiotherapy
and immunotherapy will bring the much needed change in treatment in the years to come.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Cellular membrane overview
The involvement of lipids in cell structures was first described
in 19th century when Charles E. Overton postulate the lipid nature
of cellular membranes. Lipids were considered as a cell wall com-
ponent that maintains the aqueous cytoplasm separately from the
extracellular medium. The earliest membrane organization models
were postulated 30 years later, ranging from a monolayer to atrilayer of lipids and proteins [1,2], but the most accepted is the
Fluid-mosaic model proposed by Singer and Nicolson in 1972 [3].
The fluid-mosaic model describes a bilayer of lipids in which
some proteins are embedded, where lipids are free to rotate, move
laterally or exchange between bilayers [4]. Some refinements have
been added based on further research, such as the introduction of
curvature and pore formation, membrane domains, a higher pro-
tein/lipid ratio and lipid interactions with cytoskeleton and sur-
rounding matrix, which limit the freedom of the previous model
considerably, but also adds complexity and increases functionality
[1,2,4–6].
The cellular membrane is a fundamental cell component, not
only due to the structural function but also regarding receptors,
signaling, enzymatic activity, fusion–fission, endocytosis and
transport among others, being responsible for interaction between
cell and environment. Thus, research on membranes evolved in
how to consider this cellular component, from a simple barrier
between aqueous compartments to a more complex and fascinat-
ing structure with biological functions and an identity intrinsic to
the type of cell or disease. The high lipid compositional complexity,
versatility, interactions and distribution are related to concrete
S. Zalba, T.L.M. ten Hagen / Cancer Treatment Reviews 52 (2017) 48–57 49functions of the bilayer, determining the characteristics of the
membrane or even cell. Lipid related studies revealed to be the
key to better understand and comprehend the complexity of cellu-
lar mechanisms and related pathologies [2,7–11]. In that sense,
new fields achieved importance such as cellular Lipidomics [12–
15] or Membrane Biophysics [16–19]. In spite of solid awareness
of lipid distribution, interactions and functionality, there is still a
lot to learn in this respect.
Physical properties
Lipids are composed of a polar head and a relatively long
hydrophobic tail. They tend to associate spontaneously in an aque-
ous medium due to thermodynamic forces, where hydrophobic
tails are protected by a layer of hydrophilic heads, resulting in
structures like micelles or bilayered sheets which are considered
the origin of cell membranes [4,5].
The presence of hydrophobic and hydrophilic components
allows non-covalent interaction with other lipids and proteins,
conforming cellular and organelle membranes. Lipid type and dis-
tribution within a membrane is not homogeneous. Associations,
enrichments and concrete lipid presence determine membrane
functionality, showing the important role, often undervalued, of
Lipidomics.
A well-known example is lipid asymmetry between inner and
outer membrane leaflets. There is a phospholipid enrichment con-
taining amine or serine moieties in the inner leaflet whereas cho-
line and sphingomyelins (SM) are prevailing on the outside, as is
shown in Fig. 1 [1,12].
Asymmetry maintenance is an active and energy dependent
process which requires the involvement of enzymes such as flip-
pases, scramblases and translocases [1,12,20]. The failure to pre-
serve asymmetry is associated with apoptosis and pathological
situations [1,7]. Thus, the exposure of phosphatidylethanolamine
(PE) or phosphatidylserine (PS) in the external layer is related to
an increase in aggregation and recognition by phagocytic cells,
and reacts with molecules like Annexin in apoptotic assays
[1,21]. Signaling lipids like phosphatidylinositol (PI) or phospha-
tidic acid (PA) are also enriched in the inner leaflet [7,12]. Due to
asymmetry there is a negative inner membrane surface charge that
influences hydrolysis of PI mediated by phospholipase C into inos-
itol 1,4,5-triphosphate (IP3) and Diacylglycerol (DAG), known as
second messenger molecules [11,22–24].
Finally, amine and serine moieties of the inner leaflet interact
with the cytoskeleton, which forms fences or corrals that highlyFig. 1. Schematic representation of a cellular membrane depicting a selection of phosph
saturated phospholipids and cholesterol and therefore has a relatively rigid nature with
above the transit temperature (Tm), which is typified by a more loose packing and lesslimits free lipid movement within the membrane and is involved
in membrane curvature and in mechanical cell properties
[1,21,25].
Lateral asymmetry is also widely reported resulting in polariza-
tion in some specialized tissues. In general it is assumed that apical
areas are enriched in cholesterol (Ch) and sphingolipids (SL) con-
trary to basolateral areas, which present higher amount of phos-
phatidylcholine (PC) [25,26]. This distribution is required for
barrier formation, transport and sensorial processes of intestinal
epithelial cells among other examples [25–28].
On top of that, difference in membrane composition between
organelles have been reported, explaining differences in function,
strongly related with lipid synthesis. Endoplasmic reticulum (ER)
is involved in the synthesis of glycerolipids and Ch, whereas the
Golgi complex is where the synthesis of SM and glycosphingolipid
takes place [12]. There is trafficking of lipids from these organelles
to the membrane, resulting in a gradient of SL and Ch [29,30]. Thus,
secretory organelles are 10-fold enriched in SL and Ch over the
Golgi and ER [13]. Mitochondria are typically enriched in PE and
Cardiolipin (CL) which has a bacterial origin [29], with low Ch con-
tent, whereas the ER presents higher amount of PC and PI [7,11,22].
Finally, lipid structure is involved in and affect curvature and
distortion of membranes. Phospholipids like PC or SM present a
cylindrical shape based on head and tail proportion, and due to
their amphiphilicity, spontaneously form a bilayer in an aqueous
environment (Fig. 2) [4,7,11]. Other lipids such as lyso-
phosphatidylcholine (LPC) and polyphosphoinositides, for instance
PIP2, have higher head to tail proportion and have an inverted
cone-shape, which causes a membrane positive curvature. On the
other hand PA, PE, PS, DAG, ceramides or CL are considered cone-
shaped lipids for they present small heads and distort membranes
with a negative curvature, as depicted in Fig. 2 [2,7,22,31,32].
Cone-shaped lipids may adopt non-bilayered, hexagonal and cubic,
phases temporarily on which this mesomorphism gives a high ver-
satility to the membrane [4,18,23,33]. These particular lipids influ-
ence the curvature of membrane, decreases energy required for
fission, fusion, pore formation and vesicle trafficking, whereas also
they regulate the activity of several relevant cell-signaling proteins
[4,7,24,25]. Fusion, for example, is important in differentiation dur-
ing embryogenesis and morphogenesis [34] and is involved in the
fertilization process, when the membrane of spermatozoids,
enriched in LPC, fuse with oocyte [20]. Particular lipids (PE, CL,
PA) are recruited in cell or organelle membranes, which together
with certain proteins coordinate with the cytoskeleton to carry
on fusion and fission [25–27,32].olipids as they appear in a bilayer. The liquid-ordered phase (Lo) typically harbors
a higher density of packing. The liquid-disordered phase is reached at temperatures
rigid nature.
Fig. 2. Shape and structure of phosphatidylcholine (PC), phosphatidylethanolamine (PE) and lyso-phosphatidylcholine (LPC). As is depicted, the makeup of these lipids
determine to great extend the geometry of the structures in which they participate.
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Lipids have different molecular configurations depending on
temperature. Lipids change from gel solid-ordered phase (So), with
extended hydrophobic tails at the transition temperature (Tm), to a
liquid-disordered state (Ld) where the tails are not stretched. The
Tm varies depending lipid configuration such as hydrocarbon
length, saturation degree, charge, and head group species. At tem-
peratures below Tm, lipids form a bilayer where hydrophobic
chains can interact tightly with each other, resulting in a closely
packed and rigid membrane. On the contrary, membranes at tem-
peratures above Tm are more fluid and less packed.
At body temperature, cell membrane remains in a Ld state,
because of its lipid composition, which means some degree of lat-
eral mobility within is possible [4,28]. However, apart from lipid
phases, membrane fluidity is affected by two main factors: Ch
and unsaturated lipids content [17,30,31].
Plasma membranes are generally more highly enriched in Ch
than other bilayers such as from organelles [12,31,33]. When the
Ch content is between 8 and 15%, the bilayer remains in different
degrees of Ld phase [18,35]. However, an enrichment in Ch (to
20–40%) causes an increase in membrane packing (Fig. 3), resulting
in a more rigid liquid-ordered bilayer (Lo) [28,35,36]. Both mem-
brane states Lo and Ld co-exists in membranes, especially in the
outer leaflet [28,37], as depicted in Fig. 1.
Saturation status of lipids is as well involved in packing and
fluidity. Saturated lipids favor ordered packing of membranes as
their straight hydrophobic tails interact with others through van
der Waals interactions. Unsaturated lipids have at least one cis
double bond which distort the hydrophobic chain which prevents
tight packing through steric hindrance. Thus, unsaturated lipids
like oleic acid and linoleic acid decrease lipid packing in the
membrane and consequently improve fluidity, as shown in
Fig. 3 [17,31,38–40]. On the contrary, saturated lipids like stearic
acid and palmitic acid confer a more rigid and organized mem-
brane [31,40,41].
Membrane fluidity is strongly related to permeability [40]. Pas-
sive transmembrane transport is slow for most molecules while an
increase in rigidity decreases permeability [37,40]. Comparably,
when Ch is removed from a membrane, packaging and rigidity
decreases and permeability to water increases [40]. This will be
discussed extensively in Section Lipid alterations in cancer.Membrane domains
Lipid association is very dynamic and can be activated rapidly
with little cost of energy. Typically a membrane contains areas
which present an enrichment in certain lipids, called domains,
which has important consequences for membrane properties,
organization and functionalities like cellular polarization and traf-
ficking, binding to external milieu and internal cytoskeleton, trans-
duction of signals, cell growth, migration and entry of viruses,
bacteria and nanoparticles [42–45].
There are two main lipid domains, caveolae and lipid rafts [45].
Lipid rafts are nano-sized planar formations (10–200 nm) [1,5,43],
located in the outer leaflet with an enrichment of SL and Ch
[1,43,44,46–49]. These lipid association is dynamic, reversible
and quick, where the OH– group of Ch interacts with SL via van
der Waals forces and hydrogen bonding [35,40,46,49]. The pres-
ence of these lipids is associated with a higher molecular order,
Lo, while there is a favorable combination with certain proteins
(Fig. 1).
Some authors propose the existence of two different lipid rafts,
depicted in Fig. 4: Type 1 enriched in Ch and SL, involved in cell
proliferation, and Type 2 enriched in ceramide (Cer), involved in
apoptosis [50]. Cer presents a small polar head group and a ten-
dency for self-association caused by intermolecular hydrogen
bonding allowing the formation of a relatively stable, ordered
and packed state [7,28,51]. Even small amounts of Cer are able to
displace Ch from Lo domains improving the order [18,28,52,53].
There are distinct differences between Type 1 and 2 lipid
domains. Firstly, Cer enriched lipid rafts are micro or macrodo-
mains in size, as they trend to fuse immediately after formation,
whereas Chol/SL lipid rafts are nanodomains with a very short life
(10–20 ms) [54]. Moreover, the lateral mobility in Cer domains is
slower compared to raft domains containing Ch/SL. This stabilizes
embedded proteins resulting in longer protein association [28].
As several important proteins involved in signaling are associ-
ated with lipid domains, they are considered hot spots of signaling.
The key to explain the affinity of proteins for membrane domains is
post-transcriptional protein modifications. These include acylation
with fatty acyl moieties like myristoylation of the N-terminal
amino group by amide bondage and at least a second fatty acyl
substitution on cysteines usually with palmitoyl residues
[41,47,55]. Some typical examples of proteins related with Type
Fig. 3. Different stages of lipid bilayers depending on the composition and ambient temperature. When heating up the membrane changes from a rigid Gel state (So) to a
more fluid and less dense Liquid state (Ld) when going through the transition temperature (Tm). Addition of cholesterol stabilizes the effect of temperature by providing
denser packing and an increased rigidity. Presence of unsaturated phospholipids results in impaired packing and a higher state of fluidity. The double bounds in these lipids
results in bends in the fatty chains causing repulsing and steric hindrance between the lipids.
Fig. 4. Schematics of two types of lipid rafts or lipid domains. (A) Cholesterol enriched lipid raft with EGFR embedded and part of the downstream cascade. (B) Ceramide
enriched domain with the Fas receptor embedded and the downstream apoptosis process flow chart. Epidermal growth factor (EGF), sphingomyelin (SM),
phosphatidylcholine (PC), cholesterol (Chol), phosphatidylserine (PS) and Fas-Associated protein with Death Domain (FADD).
S. Zalba, T.L.M. ten Hagen / Cancer Treatment Reviews 52 (2017) 48–57 511 lipid rafts are GPI anchored proteins [5,44], epidermal growth
factor receptor (EGFR) [47,56], estrogen receptor [57] or insulin-
like receptor (IGF-1) [47]. On the other hand, proteins located in
Type 2 domains are typically Fas (CD95), TNF-R1 or TRAIL receptor
(DR5) [9,50,53,58,59].Finally, caveolae are small surface invaginations of 50–100 nm
diameter [5,46,55] seen in many cell types [43,55]. These domains
are rich in Ch, SL and lipid-anchored proteins. They contain the
coat protein caveolin, which polymerization is essential for mem-
brane invagination [8,43,55]. Caveolae have basic properties of
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teins or act as reservoirs for rafts [43].
Lipid alterations in cancer
Lipids are regulated in response to pathological, nutritional and
pharmacological situations [7]. Although this review is focused on
cancer, lipid alteration is also involved in other diseases like car-
diopathies, diabetes, atherosclerosis, infectious diseases or neu-
rodegenerative pathologies [14,43,60].
Cancer is a disease caused by the loss of the self-control mech-
anisms of cells due to a wide variety of reasons. Main characteris-
tics of cancer cells are the ability to induce angiogenesis,
immortality and resistance to cell death, lack of response to growth
suppressor signals and the capability of invasion and metastasis.
These altered processes are indeed related with differences in lipid
composition in comparison to normal cells [10,24,60], although
these differences vary regarding type of cancer, stage and sensitiv-
ity status [10,61,62]. However, there are some common aspects in
tumoral cells, mainly related to alterations of fatty acids metabo-
lism or modification of enzymes involved in lipid metabolism
[10,36,50,63].
Typically, Ch metabolism is deregulated resulting in higher or
lower Ch amount in cancer cells compared to non-tumor cells
and therefore variations on membrane fluidity [10,17,19]. It has
been hypothesized that low Ch cells have more easy deformable
membranes and are able to enter blood vessels easier, being highly
metastatic [10]. On the other hand, multidrug resistant (MDR) cells
present higher amounts of Ch, and a more rigid membrane, which
is thus less permeable [10,64,65]. In fact, there is a significant
increase of Ch and phospholipid levels (PC, PI, PE and others) in
MDR cells, and a protein/lipid ratio elevation up to 60% in compar-
ison to sensitive cells [8,10,19]. Limitation in permeability
decreases drug uptake and explains partially treatment resistance
[10,36,64]. The increase in Ch content in tumors has been reported
to be higher than normal tissues, which can reach up to 50% [66],
and is strongly related with an increase of lipid rafts presence
[8,10,47]. These domains are involved in cell proliferation, differen-
tiation, apoptosis and migration, depending on which proteins are
located within. Thus, alterations of lipid rafts domains could be
involved in malignant transformations, uncontrolled growth, inva-
siveness and metastasis [47]. The higher amount of lipid rafts in
cancer cells allow the overexpression of growth factor receptors
like EGFR, IGF-1 or Sigma receptors [47,50,56]. Other proteins like
integrins, adherens, receptors CD44 and CD24, involved in tumor
progression and invasion, are also located in lipid rafts [42,47].
The abundance of these proteins in tumor cells are linked with a
higher invasive potential and a decreased fluidity of membranes
[65]. Besides, there is a higher presence of MDR transporters, like
P-glycoprotein (P-gp), which have an important role in MDR devel-
opment regarding the efflux of chemotherapeutics from the cyto-
plasm [10,67].
Cer metabolism has also been described as an effective drug
resistance mechanism [9,19,68–70]. Cer is present in very small
amounts in cell membranes, as intermediates in the metabolism
of the more complex SL [51] or as a result of Sphingomyelinase
(SMase) activity, which produces Cer from SM [18,28,59]. The reg-
ulation between Cer and SM is involved in differentiation, prolifer-
ation, interplay between proteins and apoptosis through intrinsic
and extrinsic pathways [70,71]. MDR cells maintain low Cer levels
by increasing SM synthesis or by preventing SM breakdown
[19,68]. In this situation there are less Type 2 raft domains (Cer
enriched) and less apoptosis. Sphingosine kinases regulate a
number of process which aid tumor progression such as survival,
proliferation and transformation which therefore provide possible
targets for therapy [72].Finally, as the inner leaflet typically consists of negatively
charged lipids as PS, in non-transformed cells, acidic pH decreases
repulsion between polar groups and surface tension giving a less
packaged membrane [19,73,74]. A slight increase in alkalinity, as
happens in resistant cells, shields the negative charges, attenuates
repulsion between polar groups and therefore increases packing.
Taken together, the interplay between the alkaline nature of the
cytoplasm of MDR cells and the makeup of the cell membrane
results in a more dense packing of lipids enhancing rigidity of
the membrane resulting in poor chemotherapeutic drug penetra-
tion of these cells [19,73,74].Membrane modulation strategies in cancer
Traditionally most cancer therapeutics are designed to interact
with proteins and nucleic acids. However, taking into account
alterations of lipid composition described above and associated
functionality in cancer cells, lipid therapy is becoming a very inter-
esting alternative. Modulation of, or interaction with, lipids could
change lipid composition, membrane properties or alter these
associated functions. Thus, it is reasonable to think that it is possi-
ble to treat cancer, or other pathologies, with lipids or molecules
that interact with lipids [24].
Cholesterol depletion
As mentioned above, Ch is the key molecule that keeps raft
domains together. Removal of Ch leads to raft and caveolae disrup-
tion and dissociation of proteins from these domains, rendering
them non-functional [43], resulting in inappropriate cellular sig-
naling events and deregulating cellular functions [16,47,50].
There are a wide variety of molecules that decrease Ch levels
[50], but only the most representative are listed below. One of
them is Filipin, a polyene macrolide that binds Ch and prevents
interaction with SL, thereby decreasing stability of membrane rafts
[47,56]. Methyl-beta-cyclodextrin (MbCD) has been also widely
used as it removes Ch rapidly but not completely [28,43]. After
treatment with these drugs Ch is depleted, rafts are disrupted
and as a result EGFR or Estrogen receptors, overexpressed in sev-
eral cancer types, are decreased [47,57,75]. Ch depletion after Emo-
din treatment has been shown to prevent cancer metastases as
well as it decreases CD44 receptor or matrix metalloproteinases
levels, suppresses tumor cell migration and impairs metastasis
establishment possibilities [47,76].
Finally, statins lower Ch levels by inhibiting the enzyme 3-
hydroxy-methylglutaryl CoA reductase (HMG-CoA reductase)
[47,75]. These drugs, traditionally prescribed to treat cardiovascu-
lar diseases, act in early stages of Ch synthesis and are able to
decrease lipid raft number and membrane rigidity. Statins cause
no effect over healthy cells compared to cancer cells but the main
activity of inhibition of HMGCoA has been found in the liver
[47,63]. Although still controversial, a cancer prophylactic effect
has been reported in statin users and currently statins are being
evaluated in clinical trials in breast cancer [63].
Stabilization of membrane domains
The strategy of Ch depletion has been used to diminish lipid
rafts and as a result impair signaling through receptors embedded
in this rafts. However, as mention in Section Membrane domains,
there are also lipid rafts which harbor pro-apoptotic receptors.
Another strategy therefore is to increase Cer levels and use lipid
rafts as platforms to induce apoptosis. As a consequence of this
approach Ch is displaced from lipid rafts Type 1 by Cer, resulting
in recruitment and aggregation of Fas/CD95 death receptors in
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[50,77]. Promotion and stabilization of these pro-apoptotic
domains accomplish an amplification of the signal [58,59]. Fas
trimerization recruits Fas-Associated protein with Death Domain
(FADD) molecules, which together with the activation of
procaspase-8 form the death-inducing signaling complex that acti-
vates caspase 3, leading to apoptosis as shown in Fig. 4b [58,59,77].
The alkyl-lysophospholipid analogue Edelfosine was the first
antitumor drug reported to induce apoptosis in cancer cells
through co-clustering of lipid rafts and Fas/CD95 death receptors
[59,77]. This molecule has a modest effect compared to reported
side-effects and is scarcely used in humans [78]. Therefore similar
compounds like Miltefosine or Perifosine, are being used as antitu-
mor lipid drugs in clinical trials [24,47,78]. Upon accumulation in
membrane rafts lipid and protein composition in cancer cells are
altered promoting recruiting of Fas ligand and apoptosis, with lim-
ited effect on normal cells [47,59,79].
Another promising compound that induces apoptosis through
recruitment of Fas/CD95 into membrane domains is Resveratrol
[47,59]. This polyphenol has been shown to have chemopreventive
and antitumor activities [59,80]. Resveratrol accumulates in lipid
rafts previous to its endocytosis [80]. Not surprisingly, good results
have been obtained with combined therapy of Resveratrol and
death receptor agonists [47].
Short chain ceramides
Chemotherapeutic treatment require interaction with the mem-
brane to enter a cell, which is one of the main barriers that limits
treatment [81,82]. The outer leaflet of the cellmembrane is believed
to provide the major barrier to permeation [37,40]. More rigid and
less permeable membranes such as presented by MDR tumor cells
challenge interaction with chemotherapeutics and impair entrance
[19]. Thus, the capability to modulate membrane fluidity/rigidity
emerges as a very useful strategy to improve a variety of treatments.
As mentioned, membrane permeability and fluidity depend on
Ch content and non-saturated/saturated lipid ratio. However, other
factors are important as well. Relatively big head groups of phos-
pholipids can inhibit the formation of tight interactions with the
surrounding lipids [28] and changes in the hydrophobic segments
of lipids can have an effect in packing tightness [83]. A good exam-
ple of how lipid structure can influence the fluidity of membrane is
provided by members of the Cer family. Cer are closely related to
sphingolipids, and several studies show that the Cer effect in mem-
branes vary regarding the length of N-acyl chain [18,52,71,83–85].
Cer molecule with chain lengths between 4 and 8 carbons is easily
incorporated into the external leaflet of cell membranes and, in
contrast to long-chained Cer, they are not able to form lipid rafts
nor increase rigidity of the membrane [18,83–85]. This is based
on the short length of the hydrophobic chain which is not able to
interact tightly with other lipids, as depicted in Fig. 5A. Thus, short
chain ceramides (SCC) increase permeability and fluidity of the
membrane when already present or when externally added and
have been used in cancer treatment for this purpose [52,81,83,85].
The more widely used SCC are N-hexanoyl-sphingomyelin and
N-octanoyl-ceramide, composed of a sphingosine backbone where
the functional amino group at position C2 is acylated with a fatty
acid and the C1 hydroxyl group is linked to a sugar moiety (glu-
cose, lactose or galactose), as shown in Fig. 5 [86].
SCCs, when pre-inserted in membranes, greatly and specifically
enhance uptake and action of various amphiphilic anticancer drugs
in cancer cells in vitro, without causing membrane leakage, toxicity
or other trivial effects by themselves [81,86,87]. Cell uptake of dox-
orubicin, a widely used amphiphilic anthracycline is improved by
the addition of SCCs and so resulting in enhanced toxicity to tumor
cells [81,86].The underlying mechanism has been studied extensively but it
is not completely elucidated yet. Studies indicate that it does not
involve a specific detergent-like membrane disruption, enhanced
endocytosis or decreased ABC transporter mediated efflux (like
Pgp), nor involved natural lipid rafts [81]. It is believed that SCCs
enhance tumor cell membrane permeability through the potential
of glycosphingolipids to form specific permeable microdomains
surrounding the drug molecule [82,87]. These microdomains con-
sist of very small channels or pores constructed of sphingolipids
with short open lifetimes (120 ns) and diameters less than 2 nm
[81,82,88] that allow passage of co-administered drugs
[81,82,86,88,89]. The working hypothesis behind pore formation
through sphingolipids is based on the observation that the short
acyl chain of SCCs cause imperfect lipid packing and hence create
local differences in membrane fluidity and lipophilicity leading to
channel formation. The specific geometry of these sphingolipids
enable a relatively sharp curvature which is needed for this
process.
Application of SCCs is proposed as a novel drug delivery
approach to enhance drug bioavailability inside tumor cells in
combination with lipid-based nanoscaled drug delivery devices
such as liposomes. These liposome carry both pro-active lipid
and chemotherapeutic drug ensuring concurrent delivery at the
very same spot [82,89–91]. It is hypothesized that in the vicinity
of tumor cells, SCC spontaneously relocate from liposomal to
plasma membrane where they self-organize into above mentioned
microdomains. Such a spontaneous redistribution, very common
for SCC analogs, results in an equilibrium between cells and lipo-
somes [90]. After transfer of SCCs to the membrane it is believed
that the encapsulated drug is released due to liposome destabiliza-
tion and the free drug enters the cell through SCC lined pores with-
out nanoparticle endocytosis [90].
Remarkably, studies indicate that SCCs seem to have a greater
impact on tumor cells compared to cells from healthy tissues.
Moreover, we (data not shown) and others observed that resistant
cells respond better to SCC pre-treatment than native sensitive
tumor cells [82,91]. Typically a cancer cell membrane is more
ordered and rigid, especially in MDR cells and SCCs seem to have
a more pronounced effect in rigid and liquid ordered membranes
with lower permeability [82,87]. The shorter hydrophobic moiety
of SCC, present properties that do not match with the structural
order of rigid membranes and as a result there is a decrease in
the order of the bilayer [85].
Cer/SM metabolism modulators
As mentioned, equilibrium between Cer and SM is related with
apoptosis or survival [68]. There are several enzymes and routes
implied in this regulation, like Glucosylceramide synthase (GCS),
an enzyme that converts Cer into SM [68,69], and SMase, that con-
verts SM to Cer phosphate (Fig. 6) [19,59].
Some cancer cells present an over expression of GCS or a down-
regulation of SMase resulting in low levels of Cer and high levels of
SM [9,19,68]. As an example, SMase downregulation through the
SMase gene hypermethylation is observed in 60% of breast tumors
[19]. Resistance development to traditional treatments like cis-
platin or irradiation are partially explained by the inhibition of
SMase, because cells failed to accumulate Cer and therefore do
not go into apoptosis [71].
Thus, modulation through down-regulation or inhibition of GCS
results in higher levels of Cer, and thus increased apoptosis and
decreased drug resistance [9,68]. Also the elevated action of SMase
reduces available SM to form lipid rafts with the resulting conse-
quences mentioned above [19,92]. TNFa, etoposide or Cytarabine
(Ara-C) are able to activate SMase enzyme, increasing Cer and
decreasing SM [9,71,92]. SMase activity could also be increased
Fig. 5. (A) Structural depiction of short and long chain ceramides within a membrane. Sphingolipids (SL), cholesterol (Ch), phosphatidylcholine (PC). (B) Molecular structures
of ceramide, sphingomyelin and three examples of short chain ceramides. The short chain ceramides can be identified by a truncated chain which is significantly shorter
compared to other.
Fig. 6. Schematic representation of the Ceramide/Sphingomyelin cycle and main strategies to modulate it in cancer therapy. Sphingomyelin conversion can be modulated
resulting in elevated levels of ceramides which favor apoptosis, while levels of ceramide can be maintained by inhibition of its processing to sphingomyelin.
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SMase gen [19]. Also the use of siRNA transfection [9,19,68], cer-
tain analogs of glucosylceramide like PDMP [68,93] or the imino
sugar OGT2378 [9,68,94], have demonstrated to inhibit and/or
decrease GCS activity and as a result SM [95]. Both strategies
decrease Ch lipid rafts and improve Cer-enriched domains in which
death receptors are located [19,59].
Lipid replacement therapy
Use of lipids in diets and supplements to increase health and
prevent illnesses has been followed for centuries [24,31]. Con-
sumption of mono and polyunsaturated fatty acids (MUFA and
PUFA), like linoleic acid [19], oleic acid [24,96] and marine fish oils
[41], is believed to have a protective effect against colon tumorige-
nesis [39,47,97]. They can influence cellular membrane composi-
tion through changing plasma properties like fluidity, phase
behavior or permeability [39,41,47]. Its inclusion in membranes
displaces acylated proteins from raft domains and reduces raft for-
mation [39,41]. The ratio between unsaturated and saturated lipids
is believed to be an important factor in cancer development and
evolution and as it is influenced by diet this field is gaining interest
fast. In fact, progression and incidence of some types of cancer like
prostate cancer has been related with high fat diet [56]. However,
the main effect of oral consumption is currently thought to be of
prophylactic nature in the case of cancer and other diseases
[24,50,60]. For this reason new analogs are being developed in
order to improve the efficacy of lipid-based or lipid-targeted
strategies such as derivatives of olive oil (Minerval) [24,60,98], of
the anesthetic propofol (Propofol-docosahexaenoic acid)
[24,98,99] or lipid analogs of traditional chemotherapeutic drugs
[24]. Minerval reduces membrane order and normalizes PE:SM
ratio in cancer cells with less effect on healthy tissue. Currently
this agent is being evaluated in phase I/II for glioma [78,98].
Finally, it has been reported that sphingolipids suppress tumor
growth by interfering with nutrient absorption. The administration
of a synthetic sphingolipid (SH-BC-893), which as well blocks other
nutrient pathways, shows favorable tumor response [100].
Lipid modulation as adjuvant for cancer therapy
Here we described the crucial importance of lipid distribution
within cell membranes and its implication in numerous important
functions. The cell membrane undergoes modifications under
specific natural conditions such as aging as well as during develop-
ment of diseases. The capability to modulate and manipulate struc-
ture, composition and properties of cell membranes has become a
very promising reality to treat diseases such as cancer [98]. Lipid
modulation, replacement or supplementation strategies revealed
indeed that cancer therapy may be improved significantly.
Reduction of Ch levels is the most advanced strategy to decrease
raft domains with survival and growth receptors, which is highly
effective in combination with a wide variety of different therapies,
from chemotherapy to radiology or immunotherapy. In fact, com-
bined with chemotherapy like Trastuzumab [47,101] and tamox-
ifen [47,102], EGCG seems to play an important role in
decreasing HER expression in multidrug resistance. Statins
improve the efficacy response and overall survival combined with
first line treatment in hepatocellular carcinoma, acute myeloid leu-
kemia or refractory multiple myeloma [63]. However, sometimes
increased Ch results in an advantage. In that way, Yang et al. com-
bined an atherosclerosis drug with immunotherapy, showing that
TCD8 cells with higher Ch level display increased TCR clustering
and underwent a more potent and efficient response [103].
The use of Cer enriched raft domains is also effective in cancer
treatment as they are related with apoptosis. A synergistic effect ofCer combined with chemotherapy, docetaxel or paclitaxel, has
been shown, which can eliminate the MDR population [104,105].
From our point of view modulation of membrane fluidity to revert
MDR resistance and increase sensitivity to chemotherapeutics is
the most promising strategy regarding lipid modulation. SCC ana-
logs demonstrated a specificity for carcinogenic tissues with a
more profound effect on tumor cells versus healthy tissues. This
class of ceramides not only reverts MDR resistance but even ele-
vates treatment to a better response compared to tumor cells
which did not develop MDR, indicating that manipulation of tumor
cell membranes has great potential in combination chemotherapy.
We and others indeed showed favorable results with a combina-
tion of SCC, alone or incorporated in nano-sized doxorubicin and
mitoxantrone delivery devices, in cancer models [89–91].
In our opinion, in depth studies of cell membranes and lipid
makeup, in other words Lipidomics, of different types of cancer
and stages will be used more often in coming years as a prognosis
and progression marker, as well as an early predictive tool together
with other biomarkers [15,106]. We believe that the modulation
and modification of membrane components will be also used as
an adjuvant in cancer and other diseases therapy.Conclusion
The cellular membrane is a uniquely organized and complex
component of the cell, responsible of maintaining cellular structure
and interaction with the environment. The knowledge of lipid
composition and especially the alterations reported in cancer pro-
vides a major opportunity to treat and prevent cancer. Understand-
ing these differences and the study on how to apply this
knowledge in cancer is part of Lipidomics, a currently underesti-
mated and underappreciated ‘‘–omic”.
In conclusion, the cell membrane and possibilities we have to
manipulate its composition and function provides a powerful tool
in the treatment of cancer either in combination with chemother-
apeutics as well as small molecules, which are currently being
developed. The cell membrane and its components must be taken
into account as key factors in cancer treatment and deserves atten-
tion for the development of new therapeutic strategies.Funding source
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